NCT03933293View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 13, 2019

Primary Completion Date

March 15, 2021

Study Completion Date

March 15, 2021

Conditions
Homozygous Familial Hypercholesterolemia
Interventions
DRUG

AK102

450mg, Q4W, subcutaneous injection

DRUG

Statins

Lipid-lowering therapies

DRUG

Ezetimibe

Lipid-lowering therapies

Trial Locations (2)

100000

Peking Union Medical College Hospital, Beijing

100029

Beijing Anzhen Hospital, Beijing

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
collaborator

AD Pharmaceuticals Co., Ltd.

INDUSTRY

lead

Akeso

INDUSTRY

NCT03933293 - A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH | Biotech Hunter | Biotech Hunter